Table 3

Summary of the meta-analysis for each cytokine

CytokinesSensitivity (95% CI)Specificity (95% CI)PLR (95% CI)NLR (95% CI)DOR (95% CI)Heterogeneity of sensitivity (I2 p)Heterogeneity of specificity (I2 p)AUC (95% CI)
IFN-γ0.72 (0.52 to 0.86)0.82 (0.76 to 0.86)4.0 (3.0 to 5.3)0.34 (0.19 to 0.62)12 (5 to 26)88.97%, <0.010%, 0.500.84 (0.80 to 0.87)
TNF-α0.70 (0.56 to 0.82)0.79 (0.64 to 0.89)3.4 (2.2 to 5.3)0.37 (0.26 to 0.53)9 (6 to 14)81.34%, <0.0180.81%, <0.010.81 (0.78 to 0.85)
IP-100.75 (0.60 to 0.86)0.74 (0.56 to 0.87)2.9 (1.8 to 4.7)0.34 (0.24 to 0.49)9 (5 to 14)84.34%, <0.0189.61%, <0.010.81 (0.77 to 0.84)
IL-20.84 (0.72 to 0.92)0.66 (0.44 to 0.82)2.5 (1.4 to 4.3)0.24 (0.13 to 0.43)10 (4 to 26)79.36%, <0.0187.31%, <0.010.84 (0.81 to 0.87)
IL-100.74 (0.62 to 0.84)0.72 (0.52 to 0.86)2.6 (1.5 to 4.5)0.36 (0.25 to 0.51)7 (4 to 15)51.98%, 0.1076.62%, 0.010.79 (0.75 to 0.83)
IL-120.50 (0.41 to 0.59)0.82 (0.74 to 0.87)2.7 (1.8 to 4.0)0.62 (0.51 to 0.75)4 (2 to 8)0%, 0.420%, 0.440.72 (0.68 to 0.76)
VEGF0.59 (0.35 to 0.80)0.87 (0.73 to 0.94)4.5 (2.5 to 8.0)0.47 (0.27 to 0.80)10 (4 to 22)85.80%, <0.0142.08%, 0.160.85 (0.81 to 0.88)
  • PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic OR; AUC, area under the curve.;